Insight

A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers

Devalingam Mahalingam/cancer.northwestern.edu

Jan 12, 2025, 19:24

A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers

A recent paper by Devalingam Mahalingam, Professor of Medicine at Northwestern University Feinberg School of Medicine, was mentioned by ACS Journal Cancer on X:

“Open Access and available now.

This clinical trial of a P-cadherin-directed therapy proved unsuccessful, but valuable lessons are learned. Further investigation may yet achieve the therapeutic potential of targeting P-cadherin.

Read the study.”

“A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers”

Authors: Devalingam Mahalingam, Taofeek Owonikoko, Ebrahim Delpassand, Catherine Wheeler, Debra Richardson et al.

A trial of radiolabeled antibody yttrium-90–FF-21101 for the treatment of advanced ovarian and other cancers :

More posts featuring ACS Journal Cancer.

ACS Journal Cancer cancer Catherine Wheeler Debra Richardson Devalingam Mahalingam Ebrahim Delpassand OncoDaily Oncology Ovarian Cancer P-cadherin Taofeek Owonikoko

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%